A Single Center, Retrospective Study assessing Impact of Background Biological Therapy on Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome
Latest Information Update: 20 Jun 2019
At a glance
- Drugs Anakinra (Primary) ; Canakinumab (Primary) ; Etanercept (Primary) ; Tocilizumab (Primary) ; Steroids
- Indications Juvenile rheumatoid arthritis; Macrophage activation syndrome
- Focus Adverse reactions
- 20 Jun 2019 New trial record
- 15 Jun 2019 Results assessing impact of biological therapy compared to non-biological therapy in Systemic Juvenile Idiopathic Arthritis-Associated Macrophage Activation Syndrome patients presented at the 20th Annual Congress of the European League Against Rheumatism.